Clinical Outcomes of Non-Stent-Based Interventions for Symptomatic Below-the-Knee Peripheral Artery Disease in the Excellence in Peripheral Artery Disease (XLPAD) Registry.

For endovascular treatment of below-the-knee (BTK) peripheral artery disease (PAD), independently adjudicated real-world outcomes comparing non-stent-based balloon angioplasty (percutaneous transluminal angioplasty) and adjunctive treatments with or without a concomitant ipsilateral femoropopliteal (FP) artery intervention are scarce. A total of 1,060 patients from the multicenter XLPAD registry who underwent non-stent-based BTK PAD intervention between 2006 and 2021 were included. The primary outcome was the 1-year incidence of major adverse limb events (MALEs), a composite of all-cause death, any amputation, or clinically driven repeat revascularization. A total of 566 patients underwent BTK and 494 BTK + FP interventions; 72% were men, with a mean age of 68.4 ± 10.9 years. Diabetes mellitus was more prevalent in the BTK-only group (76.5% vs 69%, p = 0.006). Mean Rutherford class was 4.2 ± 1.18; chronic limb-threatening ischemia was more frequent in the BTK group (55.3% vs 49%, p = 0.040). Moderate to severe calcification was more frequent in the BTK + FP group (21.2% vs 27.1%, p = 0.024), as was lesion length (110.6 ± 77.3 vs 135.4 ± 86.3 mm, p <0.001). Nearly 81% of lesions were treated with percutaneous transluminal angioplasty. Drug-coated balloon (1.6% vs 14%, p <0.001) and atherectomy (38% vs 58.5%, p <0.001) use was more frequent in the BTK + FP group. The rate of procedural success was higher in the BTK + FP group (86% vs 91%, p = 0.009), with amputation being the most common complication at 3.3% within 30 days after the procedure. The rates of 1-year MALE (21.2% vs 22.3%, p = 0.675) and mortality (4.6% vs 3.4%, p = 0.3) were similar between the BTK and BTK + FP groups. Nonstent treatment for BTK PAD with concomitant FP intervention leads to high procedural success and similar rates of 1-year MALE compared with isolated BTK intervention. Condensed Abstract: The vast majority of below-the-knee (BTK) peripheral artery disease (PAD) interventions are performed with balloon angioplasty. Presence of inflow femoropopliteal PAD in patients who undergo BTK interventions can affect the outcome of the procedure. This report explores immediate procedural success and major adverse limb events at 1 year after balloon angioplasty treatment for isolated BTK PAD and in patients who underwent an additional femoropopliteal PAD intervention.
Competing Interests: Declaration of competing interest Dr. Banerjee: honoraria: Medtronic, Boston Scientific Corporation, Kaneka; research grants (institutional): Boston Scientific Corporation, Abbott Vascular, General Electric, Esperion, Novartis, AngioSafe. Dr. Shammas: research grants: Bard/BD, AngioDynamics, Abbott, Philips, Boston Scientific; honoraria: Janssen, Boehringer Ingelheim, Bayer. Dr. Gable: W.L. Gore—Consultant, research support, Advisory Board; Medtronic—Consultant, research support; Silk Road—Consultant, research support; Teleflex—Consultant; Shape Sensing—Consultant, Advisory Board. Dr. Sayfo: Consultant: Medtronic, Boston Scientific, Shockwave, Inari, Penumbra, Cagent, AngioDynamics, Terumo, Surmodics, Imperative Care; Advisory Board: Cagent, Medtronic, Boston Scientific Corporation. Dr. Rosol: Speaker: Shockwave, Penumbra. Dr. Monteleone: Speaker: Medtronic, Boston Scientific Corporation; Advisory Board: Boston Scientific Corporation, Abbot Vascular; Consultant: Medtronic, Boston Scientific Corporation; Penumbra. Dr. Nanjundappa: Speaker: Abbott Vascular, Medtronic, ZOLL, Philips; Consultant: Medtronic, Argon, Philips. Dr. Hohmann: Speaker: Merit, Becton, Dickinson and Company, Gore, Medtronic; Consultant: Merit, Becton, Dickinson and Company. Dr. Vasquez: Speaker: Gore, Penumbra; Proctor: Terumo, Medtronic. Dr. Metzger: Honoraria: Abbott Vascular, Shockwave, Penumbra; Advisory Board: Boston Scientific Corporation, Abbot Vascular; Ownership: InspireMD. Dr. Das: Honoraria: Abbott Vascular, Livmor; Consultant: Abbott Vascular, Livmor; Research Grant: Boston Scientific Corporation. The remaining authors have no competing interests to declare.
(Copyright © 2024 Elsevier Inc. All rights reserved.)